CSF2 and COVID-19: Interestingly, the lungs of patients that experience severe COVID-19 can harbor clonally expanded Th17 cells that produce copious amounts of IL-17A and Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF), which offers a potential opportunity for therapeutic interventions that can impede GM-CSF signaling by administering anti-GM-CSF receptor monoclonal antibodies, such as mavrilimumab or lenzilumab [29,30,31].